Published in Antioxid Redox Signal on July 01, 2009
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.73
Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS One (2010) 1.63
An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A (2012) 1.45
Persistent inward currents in spinal motoneurons: important for normal function but potentially harmful after spinal cord injury and in amyotrophic lateral sclerosis. Clin Neurophysiol (2010) 0.91
State of the art and the dark side of amyotrophic lateral sclerosis. World J Biol Chem (2010) 0.89
Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD. Hum Mol Genet (2013) 0.89
Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia (2011) 0.88
Unlike physical exercise, modified environment increases the lifespan of SOD1G93A mice however both conditions induce cellular changes. PLoS One (2012) 0.86
Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing. Neuroscience (2011) 0.86
System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain (2014) 0.86
Astroglial inhibition of NF-κB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS). PLoS One (2011) 0.84
Sumoylation of the astroglial glutamate transporter EAAT2 governs its intracellular compartmentalization. Glia (2014) 0.84
Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics (2015) 0.81
Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration. J Biol Chem (2013) 0.80
Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci (2013) 0.80
Refinement of the Central Steps of Substrate Transport by the Aspartate Transporter GltPh: Elucidating the Role of the Na2 Sodium Binding Site. PLoS Comput Biol (2015) 0.79
GLT-1-Dependent Disruption of CNS Glutamate Homeostasis and Neuronal Function by the Protozoan Parasite Toxoplasma gondii. PLoS Pathog (2016) 0.78
Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol (2016) 0.78
IL-12p40 deficiency leads to uncontrolled Trypanosoma cruzi dissemination in the spinal cord resulting in neuronal death and motor dysfunction. PLoS One (2012) 0.78
Dietary Vitamin D3 Restriction Exacerbates Disease Pathophysiology in the Spinal Cord of the G93A Mouse Model of Amyotrophic Lateral Sclerosis. PLoS One (2015) 0.77
Implication of Genetic Deletion of Wdr13 in Mice: Mild Anxiety, Better Performance in Spatial Memory Task, with Upregulation of Multiple Synaptic Proteins. Front Mol Neurosci (2016) 0.76
Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis. Neuromolecular Med (2013) 0.76
Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies. Neural Plast (2016) 0.76
Novel molecular biomarkers at the blood-brain barrier in ALS. Biomed Res Int (2014) 0.76
Transgenic GDNF Positively Influences Proliferation, Differentiation, Maturation and Survival of Motor Neurons Produced from Mouse Embryonic Stem Cells. Front Cell Neurosci (2016) 0.75
Case-control study of ADARB1 and ADARB2 gene variants in migraine. J Headache Pain (2015) 0.75
Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS. Exp Neurol (2017) 0.75
Acute death of astrocytes in blast-exposed rat organotypic hippocampal slice cultures. PLoS One (2017) 0.75
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc Natl Acad Sci U S A (2017) 0.75
Transporters as Drug Targets in Neurological Diseases. Clin Pharmacol Ther (2016) 0.75
Hyperexcitability in synaptic and firing activities of spinal motoneurons in an adult mouse model of amyotrophic lateral sclerosis. Neuroscience (2017) 0.75
Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Transl Neurodegener (2017) 0.75
Effects of Glycyrrhetinic Acid on GSH Synthesis Induced by Realgar in the Mouse Hippocampus: Involvement of System [Formula: see text], System [Formula: see text], MRP-1, and Nrf2. Mol Neurobiol (2016) 0.75
Caveolin-1 Sensitivity of Excitatory Amino Acid Transporters EAAT1, EAAT2, EAAT3, and EAAT4. J Membr Biol (2015) 0.75
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 18.08
The glutamate receptor ion channels. Pharmacol Rev (1999) 15.06
Glutamate uptake. Prog Neurobiol (2001) 13.59
Calcium signaling. Cell (2007) 11.09
SUMO: a history of modification. Mol Cell (2005) 10.40
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med (1994) 8.82
ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron (2006) 7.82
Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron (1996) 7.20
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 7.19
Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci (2006) 6.53
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 6.35
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron (1997) 6.16
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron (1995) 6.03
Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature (2004) 6.02
Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci (2005) 5.97
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science (1997) 5.13
Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci (1997) 4.92
SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev (2004) 4.80
The time course of glutamate in the synaptic cleft. Science (1992) 4.68
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A (2002) 4.37
The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron (2007) 4.19
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet (1996) 4.11
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med (1992) 3.71
Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci (1994) 3.34
Glutamate receptor dynamics in dendritic microdomains. Neuron (2008) 3.28
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat Rev Neurosci (2007) 2.92
Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol (1996) 2.82
Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science (1995) 2.78
Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci (2008) 2.67
Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci (2001) 2.51
Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci (1998) 2.48
Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron (1998) 2.45
Neurodegenerative diseases and oxidative stress. Biomed Pharmacother (2004) 2.44
Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature (1996) 2.28
Neuronal glutamate transporters limit activation of NMDA receptors by neurotransmitter spillover on CA1 pyramidal cells. J Neurosci (2001) 2.26
The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci (2000) 2.18
Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science (1999) 2.17
A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev (2004) 2.14
Extracellular glutamate concentration in hippocampal slice. J Neurosci (2007) 2.13
Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem (2008) 2.08
Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci U S A (1997) 2.05
Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr Opin Neurobiol (2003) 1.99
Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem (1997) 1.90
Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.84
The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J Neurosci (2004) 1.82
Neuronal regulation of glutamate transporter subtype expression in astrocytes. J Neurosci (1997) 1.81
The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch (2003) 1.75
VGLUTs: 'exciting' times for glutamatergic research? Neurosci Res (2006) 1.72
Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol (2004) 1.61
Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol (2008) 1.59
Glutamate receptors and the induction of excitotoxic neuronal death. Prog Brain Res (1994) 1.57
Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS. Exp Neurol (2007) 1.56
The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype. Neurochem Int (1998) 1.55
Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J Neurosci (2002) 1.54
Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet (2003) 1.53
Neuronal glutamate transporters control activation of postsynaptic metabotropic glutamate receptors and influence cerebellar long-term depression. Neuron (2001) 1.50
Regulation of the glial Na+-dependent glutamate transporters by cyclic AMP analogs and neurons. Mol Pharmacol (1998) 1.49
Cerebral neurons of transgenic ALS mice are vulnerable to glutamate release stimulation but not to increased extracellular glutamate due to transport blockade. Exp Neurol (2005) 1.48
The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther (2005) 1.45
Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve (2002) 1.44
Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A (2007) 1.42
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol (2007) 1.41
Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med (Berl) (2004) 1.40
Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation. J Neurosci (1998) 1.37
SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci (1999) 1.32
Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J Neurosci Res (2002) 1.32
A trimeric quaternary structure is conserved in bacterial and human glutamate transporters. J Biol Chem (2004) 1.29
Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol (1996) 1.25
Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol Dis (2005) 1.23
Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci (2000) 1.23
AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability. J Neurosci (2000) 1.22
Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem (1996) 1.21
Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem (2006) 1.21
Metabotropic glutamate receptors: phosphorylation and receptor signaling. J Neurosci Res (2008) 1.19
On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal (2006) 1.17
Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity. J Biol Chem (2001) 1.17
A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology (1996) 1.16
Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol (2004) 1.16
Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci (2004) 1.15
Peptides released by ameboid microglia regulate astroglial proliferation. J Cell Biol (1985) 1.14
Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology (2001) 1.14
Selective potentiation of NMDA-induced neuronal injury following induction of astrocytic iNOS. Neuron (1994) 1.12
Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet (2004) 1.12
Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ (2008) 1.11
Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem (2001) 1.08
Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci (2003) 1.08
Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J Neurosci (2003) 1.07
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci U S A (2005) 1.06
Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. J Clin Invest (1993) 1.04
GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2005) 1.04
The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett (2003) 1.03
Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J Neurosci Res (2006) 1.03
Neuropathological analysis in spinal muscular atrophy type II. Acta Neuropathol (2003) 1.02
Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for excitotoxicity in ALS. J Neurochem (2003) 1.00
Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC. Neuromolecular Med (2003) 0.98
Genetic regulation of glutamate receptor ion channels. Annu Rev Pharmacol Toxicol (1999) 0.97
Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice. Exp Neurol (2006) 0.97
Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron (2004) 2.53
Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol (2008) 1.59
An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A (2012) 1.45
ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Hum Mol Genet (2010) 1.31
Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem (2006) 1.21
A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J Biol Chem (2007) 0.96
Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis (2012) 0.93
Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia (2011) 0.88
Small peptides against the mutant SOD1/Bcl-2 toxic mitochondrial complex restore mitochondrial function and cell viability in mutant SOD1-mediated ALS. J Neurosci (2013) 0.83
Voltage-dependent inwardly rectifying potassium conductance in the outer membrane of neuronal mitochondria. J Biol Chem (2010) 0.79
Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis. Neuromolecular Med (2013) 0.76